New hope for advanced prostate cancer patients, with promising new drug combo that targets genes, such as BRCA1, BRCA2, CHEK2 ...

It's a medication designed to reduce discomfort caused by a condition experienced by a majority of men during their lives.

A groundbreaking new study has found that a combination of two drugs can boost survival rates in prostate cancer patients by ...

Two U.S. Food and Drug Administration (FDA)-approved drugs for treating prostate cancer may also be effective against acute ...

Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy.

The use of alpha-blockers for benign prostatic hyperplasia is tied to an increased risk of developing acute angle-closure glaucoma, a study finds.

CHICAGO -- A prostate cancer study that could change how doctors treat some patients found that widely used hormone-blocking drugs did not improve survival chances for older men whose disease hadn't ...

Scientists have uncovered a critical weakness in prostate cancer’s defences. The disease relies on two enzymes, PDIA1 and ...

Medication burden, characterized by polypharmacy and suboptimal treatment adherence, is a predictor for acute care use among ...

Movember is back. Throughout the month of November, men are skipping their razors in favour of sporting a moustache to help ...

Experts urge men above 45 to get routine screenings and break the silence around prostate health before symptoms turn serious ...